Published in J Biol Chem on June 05, 2013
GTP is the primary activator of the anti-HIV restriction factor SAMHD1. J Biol Chem (2013) 1.09
A continuous enzyme-coupled assay for triphosphohydrolase activity of HIV-1 restriction factor SAMHD1. Antimicrob Agents Chemother (2014) 0.97
SAMHD1 specifically affects the antiviral potency of thymidine analog HIV reverse transcriptase inhibitors. Antimicrob Agents Chemother (2014) 0.89
Deoxyribonucleotides as genetic and metabolic regulators. FASEB J (2014) 0.88
SAMHD1 has differential impact on the efficacies of HIV nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother (2014) 0.87
HIV-2 infects resting CD4+ T cells but not monocyte-derived dendritic cells. Retrovirology (2015) 0.83
Substrates and Inhibitors of SAMHD1. PLoS One (2017) 0.82
Select host restriction factors are associated with HIV persistence during antiretroviral therapy. AIDS (2015) 0.81
Heterozygous colon cancer-associated mutations of SAMHD1 have functional significance. Proc Natl Acad Sci U S A (2016) 0.80
Novel inhibitors of human immunodeficiency virus type 2 infectivity. J Gen Virol (2014) 0.79
Differential regulatory activities of viral protein X for anti-viral efficacy of nucleos(t)ide reverse transcriptase inhibitors in monocyte-derived macrophages and activated CD4(+) T cells. Virology (2015) 0.77
Fidelity of classwide-resistant HIV-2 reverse transcriptase and differential contribution of K65R to the accuracy of HIV-1 and HIV-2 reverse transcriptases. Sci Rep (2017) 0.75
Dual anti-HIV mechanism of clofarabine. Retrovirology (2016) 0.75
SAMHD1 is a barrier to antimetabolite-based cancer therapies. Mol Cell Oncol (2017) 0.75
The feasibility of incorporating Vpx into lentiviral gene therapy vectors. Mol Ther Methods Clin Dev (2016) 0.75
SAMHD1 enhances nucleoside-analogue efficacy against HIV-1 in myeloid cells. Sci Rep (2017) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol (2011) 12.21
Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer (1980) 10.11
SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx. Nature (2011) 9.30
Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS (2001) 8.89
Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein. Nature (2011) 7.92
SAMHD1 restricts the replication of human immunodeficiency virus type 1 by depleting the intracellular pool of deoxynucleoside triphosphates. Nat Immunol (2012) 5.71
HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase. Nature (2011) 5.28
Recognition of a DNA operator by the repressor of phage 434: a view at high resolution. Science (1988) 4.60
SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med (2012) 4.27
SIVSM/HIV-2 Vpx proteins promote retroviral escape from a proteasome-dependent restriction pathway present in human dendritic cells. Retrovirology (2007) 3.51
Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase. J Biol Chem (2011) 3.21
Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem (2004) 3.10
SAMHD1 restricts HIV-1 reverse transcription in quiescent CD4(+) T-cells. Retrovirology (2012) 2.92
The ability of primate lentiviruses to degrade the monocyte restriction factor SAMHD1 preceded the birth of the viral accessory protein Vpx. Cell Host Microbe (2012) 2.79
Evolutionary and functional analyses of the interaction between the myeloid restriction factor SAMHD1 and the lentiviral Vpx protein. Cell Host Microbe (2012) 2.66
Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents (2008) 2.52
Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem (2003) 2.26
Tight interplay among SAMHD1 protein level, cellular dNTP levels, and HIV-1 proviral DNA synthesis kinetics in human primary monocyte-derived macrophages. J Biol Chem (2012) 2.25
SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology (2012) 1.96
HIV/simian immunodeficiency virus (SIV) accessory virulence factor Vpx loads the host cell restriction factor SAMHD1 onto the E3 ubiquitin ligase complex CRL4DCAF1. J Biol Chem (2012) 1.86
Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J Biol Chem (2010) 1.70
Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virology (2012) 1.68
Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry (2003) 1.67
A simple, versatile and efficient method to genetically modify human monocyte-derived dendritic cells with HIV-1-derived lentiviral vectors. Nat Protoc (2011) 1.54
Long-term survival and virus production in human primary macrophages infected by human immunodeficiency virus. J Med Virol (2002) 1.49
The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus. J Virol (2012) 1.47
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology (2008) 1.44
HIV infection of non-dividing cells: a divisive problem. Retrovirology (2006) 1.33
Insights into the molecular mechanism of mitochondrial toxicity by AIDS drugs. J Biol Chem (2001) 1.31
Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother (2009) 1.27
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother (2004) 1.27
Effect of antiretroviral therapy on viral load, CD4 cell count, and progression to acquired immunodeficiency syndrome in a community human immunodeficiency virus-infected cohort. Swiss HIV Cohort Study. Arch Intern Med (2000) 1.12
Inhibition of replication of HIV in primary monocyte/macrophages by different antiviral drugs and comparative efficacy in lymphocytes. J Leukoc Biol (1997) 1.07
Genetic selection in Escherichia coli for active human immunodeficiency virus reverse transcriptase mutants. Methods (1997) 1.05
Human immunodeficiency virus types 1 and 2 have different replication kinetics in human primary macrophage culture. J Gen Virol (2006) 0.89
Pre-steady state of reaction of nucleoside diphosphate kinase with anti-HIV nucleotides. J Biol Chem (1998) 0.87
Lentivirus infection of macrophages. Immunol Ser (1994) 0.84
Ovine lentivirus-infected macrophages mediate productive infection in cell types that are not susceptible to infection with cell-free virus. J Gen Virol (1999) 0.82
Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir. PLoS Med (2008) 7.46
SAMHD1 restricts HIV-1 infection in resting CD4(+) T cells. Nat Med (2012) 4.27
Flap endonuclease 1: a central component of DNA metabolism. Annu Rev Biochem (2004) 3.16
Macrophage tropism of HIV-1 depends on efficient cellular dNTP utilization by reverse transcriptase. J Biol Chem (2004) 3.10
The retroviral restriction ability of SAMHD1, but not its deoxynucleotide triphosphohydrolase activity, is regulated by phosphorylation. Cell Host Microbe (2013) 2.71
Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2009) 2.37
PB2 residue 271 plays a key role in enhanced polymerase activity of influenza A viruses in mammalian host cells. J Virol (2010) 2.35
Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J Biol Chem (2003) 2.26
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. Hepatology (2014) 2.17
Cleavage specificity of Saccharomyces cerevisiae flap endonuclease 1 suggests a double-flap structure as the cellular substrate. J Biol Chem (2002) 2.06
Monitoring medication adherence by unannounced pill counts conducted by telephone: reliability and criterion-related validity. HIV Clin Trials (2008) 2.01
Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture. Antimicrob Agents Chemother (2003) 1.99
SAMHD1 restricts HIV-1 infection in dendritic cells (DCs) by dNTP depletion, but its expression in DCs and primary CD4+ T-lymphocytes cannot be upregulated by interferons. Retrovirology (2012) 1.96
In vitro activity of structurally diverse nucleoside analogs against human immunodeficiency virus type 1 with the K65R mutation in reverse transcriptase. Antimicrob Agents Chemother (2005) 1.83
New manzamine alkaloids with activity against infectious and tropical parasitic diseases from an Indonesian sponge. J Nat Prod (2003) 1.81
Antiviral activities and cellular toxicities of modified 2',3'-dideoxy-2',3'-didehydrocytidine analogues. Antimicrob Agents Chemother (2002) 1.79
Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV neuroAIDS. J Clin Invest (2005) 1.78
On the roles of Saccharomyces cerevisiae Dna2p and Flap endonuclease 1 in Okazaki fragment processing. J Biol Chem (2004) 1.72
Lagging strand replication proteins in genome stability and DNA repair. Chem Rev (2006) 1.71
Ribonucleoside triphosphates as substrate of human immunodeficiency virus type 1 reverse transcriptase in human macrophages. J Biol Chem (2010) 1.70
Contribution of SAM and HD domains to retroviral restriction mediated by human SAMHD1. Virology (2012) 1.68
HIV-1 Vpr-induced apoptosis is cell cycle dependent and requires Bax but not ANT. PLoS Pathog (2006) 1.67
Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther (2012) 1.64
Ataxia telangiectasia mutated (ATM) and ATM and Rad3-related protein exhibit selective target specificities in response to different forms of DNA damage. J Biol Chem (2004) 1.63
WRN helicase and FEN-1 form a complex upon replication arrest and together process branchmigrating DNA structures associated with the replication fork. Mol Biol Cell (2003) 1.61
The protein components and mechanism of eukaryotic Okazaki fragment maturation. Crit Rev Biochem Mol Biol (2003) 1.57
Cu(I)-catalyzed Huisgen azide-alkyne 1,3-dipolar cycloaddition reaction in nucleoside, nucleotide, and oligonucleotide chemistry. Chem Rev (2009) 1.53
Strand transfer events during HIV-1 reverse transcription. Virus Res (2008) 1.51
Design, synthesis, and antiviral activity of 2'-deoxy-2'-fluoro-2'-C-methylcytidine, a potent inhibitor of hepatitis C virus replication. J Med Chem (2005) 1.51
Inhibition of hepatitis C replicon RNA synthesis by beta-D-2'-deoxy-2'-fluoro-2'-C-methylcytidine: a specific inhibitor of hepatitis C virus replication. Antivir Chem Chemother (2006) 1.49
The human Rad9-Rad1-Hus1 checkpoint complex stimulates flap endonuclease 1. Proc Natl Acad Sci U S A (2004) 1.49
The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus. J Virol (2012) 1.47
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology (2008) 1.44
Pif1 helicase directs eukaryotic Okazaki fragments toward the two-nuclease cleavage pathway for primer removal. J Biol Chem (2008) 1.43
A role for dNTP binding of human immunodeficiency virus type 1 reverse transcriptase in viral mutagenesis. Biochemistry (2004) 1.41
Dynamics of subgenomic hepatitis C virus replicon RNA levels in Huh-7 cells after exposure to nucleoside antimetabolites. J Virol (2003) 1.39
Reconstituted Okazaki fragment processing indicates two pathways of primer removal. J Biol Chem (2006) 1.38
Host factor SAMHD1 restricts DNA viruses in non-dividing myeloid cells. PLoS Pathog (2013) 1.37
Modification of human immunodeficiency virus type 1 reverse transcriptase to target cells with elevated cellular dNTP concentrations. J Biol Chem (2006) 1.37
Three new manzamine alkaloids from a common Indonesian sponge and their activity against infectious and tropical parasitic diseases. J Nat Prod (2004) 1.36
Dna2p helicase/nuclease is a tracking protein, like FEN1, for flap cleavage during Okazaki fragment maturation. J Biol Chem (2004) 1.34
Probing the molecular mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase using a transient kinetic analysis. Biochemistry (2003) 1.32
p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc Natl Acad Sci U S A (2013) 1.31
The 3'-azido group is not the primary determinant of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of AZT-resistant HIV-1. J Biol Chem (2005) 1.30
Mechanism of activation of beta-D-2'-deoxy-2'-fluoro-2'-c-methylcytidine and inhibition of hepatitis C virus NS5B RNA polymerase. Antimicrob Agents Chemother (2006) 1.28
Mouse SAMHD1 has antiretroviral activity and suppresses a spontaneous cell-intrinsic antiviral response. Cell Rep (2013) 1.28
Relationship between antiviral activity and host toxicity: comparison of the incorporation efficiencies of 2',3'-dideoxy-5-fluoro-3'-thiacytidine-triphosphate analogs by human immunodeficiency virus type 1 reverse transcriptase and human mitochondrial DNA polymerase. Antimicrob Agents Chemother (2004) 1.27
Manadomanzamines A and B: a novel alkaloid ring system with potent activity against mycobacteria and HIV-1. J Am Chem Soc (2003) 1.27
Antiretroviral therapy in macrophages: implication for HIV eradication. Antivir Chem Chemother (2009) 1.27
Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome. PLoS One (2010) 1.27
Pif1 helicase lengthens some Okazaki fragment flaps necessitating Dna2 nuclease/helicase action in the two-nuclease processing pathway. J Biol Chem (2009) 1.27
Dynamic removal of replication protein A by Dna2 facilitates primer cleavage during Okazaki fragment processing in Saccharomyces cerevisiae. J Biol Chem (2008) 1.24
Template dimerization promotes an acceptor invasion-induced transfer mechanism during human immunodeficiency virus type 1 minus-strand synthesis. J Virol (2003) 1.24
Single-chain estrogen receptors (ERs) reveal that the ERalpha/beta heterodimer emulates functions of the ERalpha dimer in genomic estrogen signaling pathways. Mol Cell Biol (2004) 1.23
Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol (2002) 1.23
Evidence that DNA damage detection machinery participates in DNA repair. Cell Cycle (2005) 1.23
Reduced dNTP binding affinity of 3TC-resistant M184I HIV-1 reverse transcriptase variants responsible for viral infection failure in macrophage. J Biol Chem (2008) 1.23
Restriction of diverse retroviruses by SAMHD1. Retrovirology (2013) 1.23
Saccharomyces cerevisiae flap endonuclease 1 uses flap equilibration to maintain triplet repeat stability. Mol Cell Biol (2004) 1.22
PA residues in the 2009 H1N1 pandemic influenza virus enhance avian influenza virus polymerase activity in mammalian cells. J Virol (2011) 1.22
Flap endonuclease 1. Annu Rev Biochem (2013) 1.21
Intracellular nucleotide levels and the control of retroviral infections. Virology (2012) 1.19
Acetylation of Dna2 endonuclease/helicase and flap endonuclease 1 by p300 promotes DNA stability by creating long flap intermediates. J Biol Chem (2009) 1.18
The effects of estrogen-responsive element- and ligand-induced structural changes on the recruitment of cofactors and transcriptional responses by ER alpha and ER beta. Mol Endocrinol (2002) 1.18
Okazaki fragment metabolism. Cold Spring Harb Perspect Biol (2013) 1.17
5-(Phenylthio)acyclouridine: a powerful enhancer of oral uridine bioavailability: relevance to chemotherapy with 5-fluorouracil and other uridine rescue regimens. Cancer Chemother Pharmacol (2005) 1.17
Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorg Med Chem (2006) 1.16
Evidence for IFNα-induced, SAMHD1-independent inhibitors of early HIV-1 infection. Retrovirology (2013) 1.16
Best strategies for global HCV eradication. Liver Int (2013) 1.16
Quantifying mixed populations of drug-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother (2005) 1.16
Mechanism of stimulation of human DNA ligase I by the Rad9-rad1-Hus1 checkpoint complex. J Biol Chem (2006) 1.15
Treatment as prevention and cure towards global eradication of hepatitis C virus. Trends Microbiol (2013) 1.14
Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev (2014) 1.13
Mechanistic understanding of an altered fidelity simian immunodeficiency virus reverse transcriptase mutation, V148I, identified in a pig-tailed macaque. J Biol Chem (2003) 1.13
Metabolite profiles of human immunodeficiency virus infected CD4+ T cells and macrophages using LC-MS/MS analysis. Virology (2011) 1.12
Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Curr Top Med Chem (2004) 1.12
The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One (2013) 1.12
Apparent defects in processive DNA synthesis, strand transfer, and primer elongation of Met-184 mutants of HIV-1 reverse transcriptase derive solely from a dNTP utilization defect. J Biol Chem (2008) 1.12
Assessment of the relative potency of emtricitabine and lamivudine. J Acquir Immune Defic Syndr (2003) 1.11
Mechanistic differences in RNA-dependent DNA polymerization and fidelity between murine leukemia virus and HIV-1 reverse transcriptases. J Biol Chem (2005) 1.10
Analysis of human flap endonuclease 1 mutants reveals a mechanism to prevent triplet repeat expansion. J Biol Chem (2003) 1.10
Monthly unannounced pill counts for monitoring HIV treatment adherence: tests for self-monitoring and reactivity effects. HIV Clin Trials (2011) 1.10
Flap endonuclease 1 mechanism analysis indicates flap base binding prior to threading. J Biol Chem (2010) 1.09
GTP is the primary activator of the anti-HIV restriction factor SAMHD1. J Biol Chem (2013) 1.09
Preclinical characterization of GLS4, an inhibitor of hepatitis B virus core particle assembly. Antimicrob Agents Chemother (2013) 1.08
Eukaryotic lagging strand DNA replication employs a multi-pathway mechanism that protects genome integrity. J Biol Chem (2010) 1.08